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Aims To provide insights into pathogenesis of disease progression and potential novel treatment targets for patients with
heart failure by investigation of the plasma proteome using network analysis.
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Methods
and results
The plasma proteome of 50 patients with heart failure who died or were rehospitalised were compared with
50 patients with heart failure, matched for age and sex, who did not have an event. Peptides were analysed on
two-dimensional liquid chromatography coupled to tandem mass spectrometry (2D LC ESI-MS/MS) in high definition
mode (HDMSE). We identified and quantified 3001 proteins, of which 51 were significantly up-regulated and 46
down-regulated with more than two-fold expression changes in those who experienced death or rehospitalisation.
Gene ontology enrichment analysis and protein–protein interaction networks of significant differentially expressed
proteins discovered the central role of metabolic processes in clinical outcomes of patients with heart failure. The
findings revealed that a cluster of proteins related to glutathione metabolism, arginine and proline metabolism,
and pyruvate metabolism in the pathogenesis of poor outcome in patients with heart failure who died or were
rehospitalised.
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Conclusions Our findings show that in patients with heart failure who died or were rehospitalised, the glutathione, arginine and
proline, and pyruvate pathways were activated. These pathways might be potential targets for therapies to improve
poor outcomes in patients with heart failure.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Despite the latest advances in therapy for heart failure (HF),
improving clinical outcomes remains a challenge.1–7 Whilst some
patients with HF respond to appropriate therapy, many patients
do not respond. The reason for the lack of response may be
due to differences in clinical characteristics, underlying causes,
biomarkers, genetic variants, and protein expression. Therefore,
not all patients with HF achieve benefits from the same treatment.
Plasma is a desirably accessible window into the human pro-
teome and its response to disease and therapy. However, analysis of
plasma is extremely challenging because of the wide dynamic range
of protein concentrations (10–12 orders of magnitude) and their
structural complexity.8 Only 22 highly abundant proteins comprise
99% of the plasma proteome, so the challenge is to identify candi-
date biomarkers within the 1% of medium and low abundance pro-
teins that are related to pathogenesis for clinical applications.8–12
Network analysis is a powerful tool for studying biological sys-
tems in health and disease13 that helps identify activated pathways,
driven genes or mutations in the disease. In addition, network anal-
ysis can identify subtypes of the disease, classify patients as well as
discover novel prognostic biomarkers and new targets for therapy
that might support precision medicine. Therefore, using network
analysis to compare the plasma proteome in HF patients with and
without clinical events might not only provide insights into the
pathogenesis of disease progression in HF, but might also identify
new therapeutic targets. Our aim in this study was to provide the
information about pathogenesis of disease progression and poten-
tial novel treatment targets in HF by investigation of the plasma
proteome.
Materials and methods
Patient population
Overall, 100 patients with HF in this study were selected from
the EU FP7 funded BIOSTAT-CHF (A systems BIOlogy Study to
TAilored Treatment in Chronic Heart Failure) project. This was a
multicentre clinical study in Europe14 that aimed to identify poor
outcomes in HF patients with standard treatment using a systems
biology approach (including demographics, biomarkers, genetics, and
proteomics).15–27 This project was conducted according to the Dec-
laration of Helsinki that was approved by national and local ethics
committees. All patients in this study had written informed consent.
This study recruited 2516 patients who met inclusion and exclusion
criteria according to the European Society of Cardiology guidelines.28
In brief, patients were >18 years old, presented symptoms of HF and .
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. had a left ventricular ejection fraction (LVEF)≤40% and/or B-type natri-
uretic peptide (BNP) >400 pg/mL or N-terminal pro-B-type natriuretic
peptide (NT-proBNP) >2000 pg/mL as well as were not yet treated or
treated with ≤50% of the target dose of both angiotensin-converting
enzyme inhibitor or beta-blocker at the time of recruitment. Plasma
samples were collected for proteomic analysis at the beginning of the
project. The patients were treated with standard optimised therapy
for HF, and drugs such as angiotensin-converting enzyme inhibitors and
beta-blockers were up-titrated up to 6months. Patients were then fol-
lowed up for clinical events such as death and rehospitalisation.14 There
were two groups of patients with HF in this study that were sex- and
age-matched. Fifty patients with HF (25 male) who died or were rehos-
pitalised were compared to 50 patients with HF (25 male) who did not
have an event. The baseline patient characteristics are shown in Table 1.
Plasma sample collection and storage
procedure
Blood samples of patients with HF were collected for proteomic work
on admission to the study. Blood was obtained from supine patients
after at least 15min bed rest by venepuncture that was collected in
10mL EDTA vacutainer tubes, inverted eight times and put on ice
immediately. Plasma obtained after centrifugation at 1000 g for 15min
at 4∘C was transferred to small aliquots and stored at −80∘C until
further analysis.
Sample preparation
The greatest disadvantage of using mass spectrometry-based pro-
teomics is low throughput because of time-consuming sample prepa-
ration and analysis on mass spectrometry and processing of proteomic
data. Therefore, to reduce the sample preparation, sample analysis and
data processing time, the plasma samples of patients with HF were
pooled into two biological groups that were sex- and age-matched.
One group consisted of 50 patients with HF who died or were rehospi-
talised, and they were compared to the group of 50 HF patients who did
not have an event. To do this, every plasma sample was thawed at room
temperature and vortexed to ensure homogeneity. Then, a 100 μL
aliquot of each plasma sample was taken and pooled to make two
pooled plasma samples, including one pooled sample for HF patients
with death/rehospitalisation and one pooled sample for HF patients
without events.
Two pooled plasma samples were depleted of 14 high abundance
proteins (including albumin, IgG, antitrypsin, IgA, transferrin, hap-
toglobin, fibrinogen, alpha 2 macroglobulin, alpha 1 acid glycoprotein,
IgM, apolipoprotein A I, apolipoprotein A II, complement C3, and
transthyretin) using a Multiple Affinity Removal System Human 14
(MARS 14, 4.6×100mm, Agilent Technologies,Wilmington, DE, USA),
exchanged buffers and concentrated. The samples were then reduced
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Patient characteristics in comparisons between the death/rehospitalisation heart failure group and the heart
failure group with no events
Characteristics Death/rehospitalisation (n = 50) No events (n = 50) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 76.64± 8.14 76.64± 8.14 1.000
Male sex, n (%) 25 (50) 25 (50) 1.000
Clinical profile
BMI (kg/m2) 30.01± 6.17 28.94± 6.66 0.471
Waist-to-hip ratio 1.01± 0.13 0.96± 0.10 0.018
NYHA class III/IV, n (%) 38 (76) 27 (54) 0.021
Systolic blood pressure (mmHg) 126.38± 20.63 130.94± 21.12 0.247
Diastolic blood pressure (mmHg) 66.92±11.92 69.22±12.24 0.324
Heart rate (bpm) 75.69±19.91 73.94±18.28 0.848
Outcome (death/rehospitalisation) 18/32 0/0
Time to event (median, days) 121 NA
LVEDD (mm) 56.46± 8.97 55.78±10.94 0.736
LVESD (mm) 47.75±14.03 45.09±11.91 0.758
LVEF (median, %) 40 45 0.281
HFrEF/HFpEF, n (%) 22 (44.9)/18 (36.7) 20 (43.5)/21 (45.7) 0.503
Medical history, n (%)
Hypertension 30 (60.0) 29 (59.2) 0.934
Myocardial infarction 30 (60.0) 24 (48.0) 0.229
PCI 12 (24.0) 5 (10.2) 0.069
CABG 18 (36.0) 6 (12.0) 0.005
Diabetes mellitus 21 (42.0) 13 (26.0) 0.091
Stroke 17 (34.0) 8 (16.0) 0.038
Atrial fibrillation 21 (42.0) 23 (46.9) 0.621
COPD 13 (26.0) 9 (18.0) 0.334
Peripheral arterial disease 21 (42.9) 8 (17.0) 0.006
Aetiology, n (%)
Ischaemic heart disease 40 (80.0) 31 (67.4) 0.285
Non-ischaemic heart disease 10 (20.0) 15 (32.6) 0.317
Laboratory
Serum creatinine (μmol/L) 126.88± 58.56 107.16± 34.27 0.076
eGFR (mL/min-1) 45.76±14.23 51.34±11.19 0.037
Haemoglobin (g/dL) 12.44±1.72 12.99± 2.06 0.157
Red blood cell count (million/mm3) 4.26± 0.63 4.33± 0.69 0.357
White blood cell count (1000/mm3) 9.11± 3.10 7.97± 3.82 0.016
Platelet count (1000/mm3) 256.72± 87.65 232.58± 82.51 0.194
Glucose (mg/dL) 7.10± 2.14 7.37± 3.79 0.221
Albumin (g/L) 41.10± 5.30 42.88± 4.91 0.092
HDL cholesterol (mmol/L) 1.20± 0.45 1.24± 0.35 0.319
LDL cholesterol (mmol/L) 1.65± 0.76 1.99± 0.81 0.167
ALT (U/L) 26.04±19.05 22.53±11.38 0.590
AST (U/L) 27.34±17.18 27.17±14.30 0.719
Iron (g/dL) 12.00± 5.61 13.68± 6.04 0.141
Ferritin (ng/mL) 154.23±192.84 146.94±163.08 0.446
TSH (mU/L) 2.87± 2.42 2.33± 2.14 0.184
FT4 (pmol/L) 16.90± 4.12 17.37± 3.41 0.407
Sodium (mEq/L) 140.92± 3.83 139.76± 3.66 0.064
Potassium (mEq/L) 4.18± 0.47 4.30± 0.55 0.326
HbA1c (%) 6.58±1.32 6.66±1.48 0.822
NT-proBNP (pg/mL) 6321.58± 7557.40 2616.38± 3442.63 0.003
Medication, n (%)
ACE/ARB 30 (60.0) 38 (76.0) 0.086
Beta-blocker 34 (68.0) 37 (74.0) 0.509
Aldosterone antagonist 14 (28.0) 14 (28.0) 1.000
Loop diuretic 48 (96.0) 47 (94.0) 0.646
Digoxin 6 (12.0) 11 (22.0) 0.183
ACE, angiotensin-converting enzyme; ALT, alanine transaminase; ARB, angiotensin receptor blocker; AST, aspartate transaminase; BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic
obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; FT4, free thyroxine; HbA1c, glycated haemoglobin; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure
with reduced ejection fraction; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular
end-systolic diameter; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; TSH, thyroid stimulating hormone.
and alkylated before digestion with trypsin to peptides. Onemg of each
pooled sample was injected on a Gemini column to separate peptides
(Gemini NX C18 110Å, 150× 2mm, 3 μm particles, Phenomenex,
Cheshire, UK) using a 110min gradient in liquid chromatography.
This step was performed offline on a high performance liquid .
..
..
..
..
..
. chromatography (HPLC) system (Waters Corporation, Manchester,
UK) which includes a Waters 600S controller, a Waters 486 Tunable
Absorbance Detector and a Waters 626 Pump (Millipore, USA).
Peptides were collected at every minute and were concatenated into
20 fractions by combining pre-concatenation fractions 1, 21, 41, 61,
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and 81; 2, 22, 42, 62 and 82; and so on. Twenty fractions were made
in this study because a balance was required in order to achieve high
throughput and sensitivity of protein identification. A schematic of the
proteomic workflow to discover significant differentially expressed
proteins in patients with HF is shown in the online supplementary
Figure S1.
Liquid chromatography electrospray
ionisation mass spectrometry/mass
spectrometry analysis
A Waters Synapt G2 High Definition Mass Spectrometry (HDMS) sys-
tem (Waters Corporation) was employed to analyse the HF samples in
this study. This is a hybrid, quadrupole, ion mobility, orthogonal accel-
eration, time of flight mass spectrometer controlled by the MassLynx
4.1. A NanoLockSpray Electrospray Ionisation (ESI) source is fitted
as standard equipment and a nanoAcquity Ultra Performance Liquid
Chromatography (UPLC) system was coupled online. The sample was
introduced into the source through an emitter with a flow rate of
0.3 μL/min.
Using the fractionation and concatenation method, each HF group
had a total of 20 concatenated samples that were analysed on liq-
uid chromatography electrospray ionisation mass spectrometry/mass
spectrometry (LC ESI-MS/MS) in ion mobility LC-data independent
acquisition mass spectrometry (HDMSE) mode. One μg of each frac-
tion was analysed in each run. Fractions were analysed randomly and
the same fraction of both HF groups was analysed at the same time.
Each fraction was analysed in triplicate using a 50min gradient in LC
ESI-MS/MS in HDMSE mode. The column was washed by three injec-
tions of a 20min run (1× 20% isopropanol, 1×methanol, and 1× 0.1%
formic acid) between each triplicate injection to avoid carryover.
Quality control
The use of a quality control (QC) is necessary in proteomic exper-
iments for analysing samples over a long period of time in order to
maintain a high standard of obtained results. At the same time of
making two pooled HF plasma samples, a 10 μL aliquot of each plasma
sample was also taken from 100 HF plasma samples and pooled
together to make a QC plasma sample. This pooled QC sample
was prepared and analysed throughout the whole experiment as the
pooled HF samples. The QC sample was analysed in triplicate at the
beginning of the experiment, then in the middle of the experiment,
and at the end of the experiment on mass spectrometry along with
the pooled HF plasma samples that allows the intra-study assessment
of data quality. The chromatography of every QC sample was assessed
on MassLynx 4.1 and PLGS 2.5 processed the raw data. If the chro-
matography and the total number of proteins identified were similar
to the first QC sample, then the next samples were analysed.
Data analysis and statistics
Progenesis QI for Proteomics (Nonlinear Dynamics, Manchester, UK)
enabled the identified and quantified proteins to be compared between
two HF groups. The database was downloaded from UniProtKB
database (Human) in FASTA format. Data processing parameters were
minimum of two fragments per peptide, minimum of five fragments per
protein, and minimum of two peptides per protein. The database was
searched by using strict trypsin cleavage rules, two missed cleavages
were allowed. Fixed modification of cysteine (Carbamidomethyl C) was ..
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.. selected. The variable modifications were Deamidation N, Oxidation
M and Phosphoryl STY. The false rate discovery (FDR) for identification
at the protein level was set to a maximum rate of 1%. Data generated
using the Progenesis QI was exported toMicrosoft Excel where further
data analysis was performed. A multivariate statistical analysis was
conducted on proteins and a further filter on proteins was applied
based on the P-value and fold change to identify the expression of
proteins of interest.
The statistical software SPSS 24.0 (Statistical Package for the Social
Sciences, Chicago, IL, USA) for Windows was employed for statisti-
cal analyses in this study. Values were compared by using Student’s
t-tests for two group comparisons. All statistical tests were performed
two-tailed, and a P-value <0.05 was considered statistically significant.
Proteins with a fold change ≥2 and at a P-value <0.05 were significant
differentially expressed proteins.
ProteinCenter software (Thermo Scientific) was employed to anno-
tate significant differentially expressed proteins identified using Gene
Ontology (GO terms) in order to classify them into biological pro-
cesses such as metabolic processes, cellular homeostasis and so on.
Mapping of significant differentially expressed proteins and pathway
analysis were performed using Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway database. The protein–protein interaction
network analysis obtained by using ClueGO plug-in from Cytoscape
version 3.6.1. Cytoscape is a bioinformatics platform that is able
to visualise and analyse networks. With ClueGO plug-in built in
Cytoscape, GO terms and KEGG pathways are integrated into a func-
tionally organised network that is able to compare the biological roles
of significant differentially expressed proteins.
Results
Patient characteristics
Patient characteristics of the HF cohort in this study are described
in Table 1. Both HF (death/rehospitalisation and no events) groups
were matched for age (average age: 76.6± 8.1 years) and gender.
In the HF patients with events, estimated glomerular filtration rate
was lower (45.76±14.23mL/min-1 vs. 51.34±11.19mL/min-1;
P = 0.037) and white blood cell count (1000/mm3) was higher
(9.11± 3.10 vs. 7.97± 3.82; P = 0.016). More patients were in
New York Heart Association (NYHA) class III/IV (76% and 54%
for HF with death/rehospitalisation and no events, respectively;
P = 0.021). In addition, waist-to-hip ratio was higher (1.01± 0.13
vs. 0.96± 0.10; P = 0.018) and more patients had medical his-
tory of coronary artery bypass surgery (18 vs. 6; P = 0.005)
and peripheral arterial disease (21 vs. 8; P = 0.006) in patients
with events. NT-proBNP levels were higher in HF patients with
events (6321.58± 7557.40 pg/mL vs. 2616.38± 3442.63 pg/mL;
P = 0.003). All other patient characteristics were not significantly
different between the two HF groups.
Quantitative proteomics
and identification of over- or
under-expressed proteins
A total of 3001 quantified plasma proteins were identified in
both HF groups that corresponded to a total of 57 718 pep-
tides at FDR of 1% using two-dimensional (2D) LC-ESI-MS/MS
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Volcano plot for proteins identified in both heart
failure groups. The volcano plot displays proteins identified
with differential expressions between both heart failure groups
(death/rehospitalisation vs. no events). The horizontal axis
(x-axis) corresponds to the log 2 fold change value and the ver-
tical axis (y-axis) describes the negative value of log 10 (P-value).
The red dashed line represents P = 0.05 and the blue dashed lines
represents the fold change = 2.
in HDMSE mode and label-free quantification. There were 1426
up-regulated proteins and 1562 down-regulated proteins in the
death/rehospitalisation HF group in comparisons with HF group
with no events (Figure 1). In addition, there were 97 proteins iden-
tified in both HF groups that were over- or under-expressed sig-
nificantly with expression changes more than two-fold at P < 0.05
in the comparison between the death/rehospitalisation HF group
and HF group with no events, including 51 up-regulated and 46
down-regulated proteins in the death/rehospitalisation HF group
(Table 2; online supplementary Table S1 and Figure S2).
Functional classification of significant
differentially expressed proteins
A GO analysis was performed in order to obtain a GO clas-
sification for the 97 significant differentially expressed proteins
in patients with HF. The GO analysis of these proteins revealed
involvement in multiple biological processes in HF. The highest pro-
portions of 21.4% (59) proteins were found to be involved with
metabolic processes in the biological processes of 97 significant
differentially expressed proteins; 20.3% (56) proteins were related
to the regulation of biological processes. The response to stim-
ulus, cell organisation and biogenesis, and transport contributed
to 14.9% (41), 12.0% (33) and 9.8% (27) proteins, respectively.
The remaining proteins were involved with various biological pro-
cesses such as cellular component movement (3.6%, 10 proteins),
cell differentiation (3.6%, 10 proteins), defense response (3.3%,
nine proteins), cellular homeostasis (2.2%, six proteins), cell death
(1.8%, five proteins), cell division (1.1%, three proteins), develop-
ment (1.1%, three proteins), cell growth (0.7%, two proteins), cell
proliferation (0.7%, two proteins), coagulation (0.4%, one protein), ..
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.. and cell communication (0.4%, one protein). Figure 2 displays GO
enrichment analysis of significant differentially expressed proteins
in patients with HF.
Protein–protein interaction analysis
of significant differentially expressed
proteins
To explore the protein–protein interaction information of sig-
nificant differentially expressed proteins the functional overview
of 97 significant differentially expressed proteins was performed
using Cytoscape software version 6.3.1 with ClueGO plug-in. GO
enrichment analysis and KEGG pathway of significant differen-
tially expressed proteins revealed the central role of metabolic
processes in clinical outcomes of patients with HF. The findings sug-
gested that a cluster of proteins related to glutathione metabolism,
arginine and proline metabolism, and pyruvate metabolism
in the pathogenesis of poor outcome in patients with HF
(Figure 3).
Discussion
A total of 3001 proteins with quantification in both HF groups
were identified using plasma proteome, with many of those over-
or under-expressed in the HF group with death/rehospitalisation
as compared to the HF group with no events. We further
explored the 97 proteins with a differential expression more
than two-fold at P < 0.05 in the comparison between two HF
groups (death/rehospitalisation vs. no events). These results sug-
gest that a wide range of proteins might be related to several
pathophysiological processes in HF. Functional annotation of these
results using GO, KEGG and protein–protein interaction net-
works revealed the complex functions of the proteomic interac-
tome in the pathogenesis of poor outcome of patients with HF
(Figure 2 and Figure 3). KEGG pathway analysis suggested that a
cluster of significant differentially expressed proteins relates to
glutathione metabolism, arginine and proline metabolism, and pyru-
vate metabolism in the pathogenesis of disease progression in HF
and their involvement with clinical outcomes in patients with HF
(Figure 3).
Glutathione metabolism as a potential
target for therapy in heart failure
The proteomic data in this study revealed the involvement
in glutathione metabolism of differentially expressed pro-
teins that includes gamma-glutamylcyclotransferase (GGCT),
lactoylglutathione lyase (GLO1), glutathione S-transferase
Mu 5 (GSTM5), microsomal glutathione S-transferase 3
(MGST3), and spermidine synthase (SRM). The glutathione
(L-gamma-glutamyl-cysteinyl-glycine) is an antioxidant that plays
an important role in vascular and cardiac function29,30 and deter-
mines cell survival.31,32 Glutathione deficiency is involved with
HF progression and cardiac remodelling in animal models and
humans. Adamyl et al.29 found that the left ventricle of human
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 List of significant differentially expressed proteins with a fold change more than 10 in comparisons between
both heart failure groups
Protein name Gene Fold change Expression P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Copine-2 CPNE2 11.40 Up 0.0292
DnaJ homolog subfamily C member 7 DNAJC7 12.48 Up 0.0002
Dysferlin DYSF 12.47 Up 0.0412
FERM domain-containing protein 7 FRMD7 0.10 Down 0.0141
Matrix metalloproteinase 9 MMP9 0.06 Down 0.0464
Mucolipin-3 MCOLN3 0.07 Down 0.0285
Nuclear pore complex protein Nup98-Nup96 NUP98 20.43 Up 0.0462
Nucleolar RNA helicase 2 DDX21 15.30 Up 0.0137
Protein FAM49B FAM49B 26.91 Up 0.0043
Protein phosphatase 1 regulatory subunit 14B PPP1R14B 33.57 Up 0.0130
Regulator of G-protein signalling 10 RGS10 0.10 Down 0.0386
Trafficking kinesin-binding protein 1 TRAK1 22.27 Up 0.0281
Transcription elongation factor SPT4 SUPT4H1 79.28 Up 0.0144
Fold change: ratio of heart failure with death/rehospitalisation:heart failure with no events.
The rest of significant differentially expressed proteins is presented in the online supplementary Table S1.
failing heart was depleted in total glutathione by 54%. In addition,
the authors demonstrated that there was a glutathione deficiency
in the left ventricle in 2-month post-myocardial infarction rats
with chronic HF. Interestingly, treatment with the glutathione
precursor N-acetylcysteine for 1month normalised glutathione in
the left ventricle, improved left ventricular contractile function,
and lessened adverse left ventricular remodelling in 3-month
post-myocardial infarction rats.29 Another study by Damy et al.33
discovered that glutathione deficiency was involved with the
functional status and structural cardiac abnormalities of patients
with cardiac diseases. The results from their study showed that
compared to healthy controls, blood glutathione levels in patients
with coronary artery disease were decreased by 21% in patients
with NYHA class I and by 40% in patients with NYHA class II
to IV. Moreover, blood glutathione levels in the atrial tissue were
severely depleted by 58% in patients with NYHA class IV as
compared to patients with NYHA class I.33 In a community-based
case-control study (Hisayama Study), Shimizu et al.34 found that the
frequency of diabetes and systolic and diastolic blood pressures
reduced with elevating glutathione levels. In addition, there were
significantly lower glutathione levels in the cerebral infarction and
haemorrhage cases as compared to the corresponding control
groups. The authors concluded that the reduction of glutathione
levels in plasma may be an independent risk factor for the devel-
opment of cardiovascular disease. Kovacs et al.35 investigated the
link between myocardial infarction and glutathione S-transferase
polymorphism in patients that underwent cardiac surgery using
genetic tests. The results suggested that the presence of allele B
might have a potential role for protecting in the development of
myocardial infarction, while the presence of alleles A and C could
be associated with an increased risk of myocardial infarction. The
findings about the involvement of differentially expressed proteins
linked with glutathione metabolism in this study suggest that
glutathione metabolism may be an interesting therapeutic target
for HF. .
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. Arginine and proline metabolism
as potential targets for therapy in heart
failure
The proteomic results in this study found differentially expressed
proteins such as 4-trimethylaminobutyraldehyde dehydrogenase
(ALDH9A1), prolyl 4-hydroxylase subunit alpha-1 (P4HA1) and
SRM, which are responsible for arginine and proline metabolism.
SRM also participates in glutathione metabolism (see above).
Arginine is a precursor for the synthesis of proteins, nitric oxide,
urea, polyamines, proline, glutamate, creatine, and agmatine36
and plays an important role in the oxidation of energy substrates
in adipocytes, heart, liver, skeletal muscle, and other tissues.
Arginine reverses endothelial dysfunction in patients with major
cardiovascular risk factors (hypercholesterolaemia, smoking,
hypertension, diabetes, obesity/insulin resistance, and aging) and
improves cardiovascular disorders (coronary and peripheral arte-
rial disease, ischaemia/reperfusion injury, and HF).37 HF is related
to decreased plasma arginine levels. Investigating the effects of
L-arginine in chronic HF, Bocchi et al.38 found that L-arginine
decreased heart rate, mean systemic arterial pressure, systemic
vascular resistance, and increased right atrial pressure, cardiac
output, stroke volume. The authors concluded that L-arginine
improved cardiac function by reversing endothelial dysfunction
with no effect on left ventricular contractility. Another study by
Hambretch et al.39 also demonstrated that endothelial dysfunction
in patients with HF can be improved by dietary supplementation
with L-arginine. Moreover, Rector et al.40 indicated that sup-
plemental oral L-arginine significantly increased forearm blood
flow during forearm exercise, increased distances during a 6-min
walk test, lowered scores on the Living with HF questionnaire,
improved arterial compliance, and reduced circulating levels of
endothelin. Fan et al.41 demonstrated that arginine pathways in
patients with acute myocardial infarction were activated as com-
pared to unstable angina patients by using plasma metabolomic
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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(A)
(B)
Figure 2 Gene ontology (GO) enrichment analysis of significant differentially expressed proteins in patients with heart failure with poor
outcomes. (A) Proportions of significant differentially expressed proteins that were found in involving with biological processes. (B) Numbers
of significant differentially expressed proteins that correspond to biological processes.
profiles. Furthermore, the pathway analysis by Wang et al.42
indicated that arginine and proline metabolism were affected in
unstable angina patients complicated with diabetes. Therefore,
arginine metabolism may be an interesting therapeutic target and
supplementation of arginine could have beneficial effects in HF.
Pyruvate metabolism as a potential
target for therapy in heart failure
Pyruvate metabolism dysregulation was also suggested from the
differentially expressed proteins in this study such as ALDH9A1 .
..
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. (shared with arginine and proline metabolism), dihydrolipoyl dehy-
drogenase mitochondrial (DLD) and GLO1 (shared with glu-
tathione metabolism). Pyruvate is a keystone molecule for many
aspects of metabolism in human. Pyruvate plays an important
role for mitochondrial ATP generation in mitochondria by oxida-
tive phosphorylation and for driving multiple biosynthetic path-
ways intersecting the citric acid cycle.43 Mutations of the genes
encoding for proteins that regulate pyruvate metabolism may lead
to many diseases. Pyruvate is an important source of energy
for myocardium as an intermediate in Krebs cycle. Hermann
et al.44 demonstrated that application of pyruvate into the left main
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Protein–protein interaction networks of significant differentially expressed proteins revealed the central role of metabolism in poor
clinical outcomes of patients with heart failure. A cluster of significant differentially expressed proteins is displayed that relates to glutathione
metabolism, arginine and proline metabolism, and pyruvate metabolism in the pathogenesis of disease progression in heart failure and their
involvement with poor clinical outcomes in patients with heart failure. The expression of these significant differentially expressed proteins is
presented in more details in the online supplementary Table S1. ALDH9A1, 4-trimethylaminobutyraldehyde dehydrogenase; DLD, dihydrolipoyl
dehydrogenase mitochondrial; GGCT, gamma-glutamylcyclotransferase; GLO1, lactoylglutathione lyase; GSTM5, glutathione S-transferase Mu
5; MGST3, microsomal glutathione S-transferase 3; P4HA1, prolyl 4-hydroxylase subunit alpha-1; SRM, spermidine synthase.
coronary artery in patients with congestive HF with NYHA class III
resulted in a 23% increase in cardiac index, a 38% increase in stroke
volume index, a 36% decrease in pulmonary capillary wedge pres-
sure, and heart rate decreased significantly by 11%. The authors
suggest that the inotropic effect of pyruvate was associated with a
significant decrease in heart rate in contrast to catecholamines and
phosphodiesterase inhibitors. Another study showed that pyruvate
increases the free energy from ATP hydrolysis and the sarcoplas-
mic reticulum (SR)-calcium gradient.45 Moreover, Hasenfuss et al.46
indicate that application of pyruvate improves contractile perfor-
mance of failing human myocardium by increasing intracellular Ca2+
transients and myofilament Ca2+ sensitivity. The effects of pyruvate
on the SR calcium pump function are very interesting because SR
calcium pump dysfunction has a pivotal role in the pathogenesis
of HF.47 Fatima et al.48 demonstrated a disturbance of the pyru-
vate pathway in patients with coronary artery disease as compared
to young healthy volunteers. Improving pyruvate availability could
therefore be a novel approach to treat patients with HF.
Heart failure is a complex clinical syndrome at the end stage
of heart disease that is comprised of multiple pathophysiologi-
cal processes. The plasma is easily accessible for clinical use and
the largest representation of the human proteome in which many
proteins are related to pathogenesis for clinical applications. How-
ever, the greatest challenge in analysing plasma proteome is the
wide dynamic range of protein concentrations.8 To the best of our
knowledge, this is the first study that performed 2D LC ESI-MS/MS
in HDMSE combined with an immunodepletion method on a MARS
14 column along with using a sample pooling strategy for patients ..
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.. with HF. This proteomic pipeline was a reasonable approach that
helped to overcome the low throughput and time-consuming steps
in mass spectrometry-based proteomics and achieved a much
greater identification of low abundant proteins in plasma. A wide
range of differentially expressed proteins identified in this study not
only provided more information about pathogenesis of disease pro-
gression in HF, but also discovered potential novel treatment tar-
gets for design of new drugs to improve poor outcomes in patients
with HF. In addition, with this plasma proteomic approach a panel of
multiple biomarkers in HF could be designed and developed that
would be able to predict clinical events and treatment response
with an improvement of precision and robustness because an ideal
single biomarker may not exist for HF due to the participation
of multiple pathogenic processes. Furthermore, these differentially
expressed proteins identified could be employed to investigate
pathogenic genomic loci in HF.
There was little literature about proteomic studies in patients
with HF. In a recent proteomic study published by our group, 49
differently expressed proteins were identified between deaths
(n = 45) and survivors (n = 45) in patients with HF. How-
ever, Emmens et al.23 focused on a depth investigation of the
multifunctional HDL proteome to reveal underlying pathophysi-
ological mechanisms that could explain the association between
HDL and clinical outcome, while this study covered the whole
plasma proteome in patients with HF. In another proteomic study
by Stenemo et al.,49 18 proteins were identified with several novel
associations between proteins involved in apoptosis, inflammation,
matrix remodelling, and fibrinolysis with incident HF. However,
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Schematic plasma proteomic approach to understand the pathogenesis and its link with clinical outcomes in patients with heart
failure.
this study was performed in a HF cohort with elderly individuals
and Proseek Multiplex cardiovascular disease I96 x 96 proximity
extension assay technique was used to assess proteins previ-
ously associated with cardiovascular pathology. Farmakis et al.50
identified a set of 107 specific peptide biomarkers in HF with
reduced ejection fraction (HFrEF) patients with chronic kidney
disease (59 HFrEF patients vs. 67 controls). However, the capillary
electrophoresis–mass spectrometry analysis was performed in
this study using urine proteome.
Future perspectives
The results in this study showed that plasma proteomics provides
insights into the pathogenesis of disease progression in HF that
would open new perspectives for translational research. The find-
ings in this study also suggested that glutathione metabolism, argi-
nine and proline metabolism, and pyruvate metabolism are involved
in the progression of HF. They may be potential therapeutic tar-
gets that might provide potential additive therapeutic interventions
for patients with HF. Therapies that modulate glutathione, arginine
and pyruvate metabolism could have beneficial effects in HF by
improving cardiac function and endothelial dysfunction that would
be a topic for future investigation.
Strengths and limitations
To the best of our knowledge, this is the first study using a plasma
proteomic approach (2D LC ESI-MS/MS in HDMSE) to increase .
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. the understanding about the pathogenesis of HF and its link with
clinical outcomes in patients with HF. The results obtained in this
study demonstrated that 2D LC ESI-MS/MS in HDMSE combined
with a multiple affinity removal system (MARS 14) is an informative
feasible approach for providing insight into the pathogenesis of HF
and discovery of potential biomarkers in plasma of patients with HF
(Figure 4). Moreover, novel therapeutic targets could be identified
for design of new drugs to improve poor outcomes in HF.
This study has several limitations. First, the sample size
of this proteomic study was limited to 50 HF patients with
death/rehospitalisation vs. 50 HF patients without events because
these 100 patients with HF had the outcomes that were age-
and sex-matched at the time when the proteomic work was
conducted. Therefore, the findings in this study will need to be
validated in another large cohort. Second, sample pooling may
lead to a loss of some inter-individual biological information in
plasma.51 However, pooling of samples in proteomics is a valid
and valuable procedure,52 necessitated by the detailed analyses
and large peptide/protein datasets in a low-throughput work-
flow. Third, the method of immunoaffinity depletion for the top
14 high abundant proteins (MARS 14) in plasma was used to
achieve a greater detection of low abundant proteins,53 but some
nontargeted proteins might be removed along with the targeted
proteins. Fourth, the differences of plasma proteomes between
two subgroups (rehospitalisations vs deaths) in the group of HF
patients with clinical events could not be analysed due to the
procedure of sample pooling. Fifth, only Caucasian patients were
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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recruited in the BIOSTAT-CHF project due to the study design.
Therefore, the results of this study may need replication in patients
of non-Caucasian ethnicity.
Conclusions
From 3001 proteins identified with quantification, 97 were differ-
entially expressed between HF patients with and without clinical
events. A network analysis with pathway enrichment identified that
pathways related to glutathione metabolism, arginine and proline
metabolism, and pyruvate metabolismwere activated in HF patients
with clinical events. These findings imply that glutathione, argi-
nine and pyruvate might be potential therapeutic targets to further
improve clinical outcomes in HF.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Schematic of the proteomic workflow to discover
significant differentially expressed proteins in patients with heart
failure.
Figure S2. Heatmap showing the expression profiles of 97 signif-
icant differentially expressed proteins in comparing between both
heart failure groups.
Table S1. List of significant differentially expressed proteins with
properties in patients with heart failure.
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